Big Pharma Split Stock Net Income
| PRM Stock | CAD 14.73 0.23 1.59% |
As of the 8th of February, Big Pharma shows the mean deviation of 1.32, and Risk Adjusted Performance of 0.1538. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Big Pharma, as well as the relationship between them.
Big Pharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 6.6681 | Revenue | Earnings Share (1.95) |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 11.6 K | 11 K | |
| Net Loss | -619.4 K | -588.4 K | |
| Net Loss | -484.8 K | -460.5 K | |
| Net Loss | (0.54) | (0.51) | |
| Net Income Per E B T | 0.19 | 0.22 |
Big | Net Income |
Evaluating Big Pharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Big Pharma Split's fundamental strength.
Latest Big Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Big Pharma Split over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Big Pharma Split financial statement analysis. It represents the amount of money remaining after all of Big Pharma Split operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Big Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Big Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (538.62 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Big Net Income Regression Statistics
| Arithmetic Mean | 1,049,458 | |
| Geometric Mean | 591,154 | |
| Coefficient Of Variation | 181.66 | |
| Mean Deviation | 1,460,629 | |
| Median | 323,221 | |
| Standard Deviation | 1,906,496 | |
| Sample Variance | 3.6T | |
| Range | 6.4M | |
| R-Value | 0.07 | |
| Mean Square Error | 3.9T | |
| R-Squared | 0 | |
| Significance | 0.79 | |
| Slope | 26,628 | |
| Total Sum of Squares | 58.2T |
Big Net Income History
Big Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Big Pharma is extremely important. It helps to project a fair market value of Big Stock properly, considering its historical fundamentals such as Net Income. Since Big Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Big Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Big Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Big Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Big Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Big Pharma.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Big Pharma on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Big Pharma Split or generate 0.0% return on investment in Big Pharma over 90 days. Big Pharma is related to or competes with Bankers Petroleum, Elysee Development, NMC Resource, and RE Royalties. Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc More
Big Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Big Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Big Pharma Split upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.06 | |||
| Information Ratio | 0.1343 | |||
| Maximum Drawdown | 8.28 | |||
| Value At Risk | (2.72) | |||
| Potential Upside | 4.06 |
Big Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Big Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Big Pharma's standard deviation. In reality, there are many statistical measures that can use Big Pharma historical prices to predict the future Big Pharma's volatility.| Risk Adjusted Performance | 0.1538 | |||
| Jensen Alpha | 0.3023 | |||
| Total Risk Alpha | 0.1436 | |||
| Sortino Ratio | 0.118 | |||
| Treynor Ratio | 1.3 |
Big Pharma February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1538 | |||
| Market Risk Adjusted Performance | 1.31 | |||
| Mean Deviation | 1.32 | |||
| Semi Deviation | 1.27 | |||
| Downside Deviation | 2.06 | |||
| Coefficient Of Variation | 543.54 | |||
| Standard Deviation | 1.8 | |||
| Variance | 3.26 | |||
| Information Ratio | 0.1343 | |||
| Jensen Alpha | 0.3023 | |||
| Total Risk Alpha | 0.1436 | |||
| Sortino Ratio | 0.118 | |||
| Treynor Ratio | 1.3 | |||
| Maximum Drawdown | 8.28 | |||
| Value At Risk | (2.72) | |||
| Potential Upside | 4.06 | |||
| Downside Variance | 4.22 | |||
| Semi Variance | 1.61 | |||
| Expected Short fall | (1.48) | |||
| Skewness | 0.3226 | |||
| Kurtosis | 0.273 |
Big Pharma Split Backtested Returns
Big Pharma appears to be very steady, given 3 months investment horizon. Big Pharma Split secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Big Pharma Split, which you can use to evaluate the volatility of the firm. Please makes use of Big Pharma's risk adjusted performance of 0.1538, and Mean Deviation of 1.32 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Big Pharma holds a performance score of 13. The firm shows a Beta (market volatility) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Big Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Big Pharma is expected to be smaller as well. Please check Big Pharma's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Big Pharma's price patterns will revert.
Auto-correlation | 0.34 |
Below average predictability
Big Pharma Split has below average predictability. Overlapping area represents the amount of predictability between Big Pharma time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Big Pharma Split price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current Big Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Big Operating Income
Operating Income |
|
Based on the recorded statements, Big Pharma Split reported net income of (538,624). This is 100.04% lower than that of the Capital Markets sector and 100.2% lower than that of the Financials industry. The net income for all Canada stocks is 100.09% higher than that of the company.
Big Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Big Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Big Pharma could also be used in its relative valuation, which is a method of valuing Big Pharma by comparing valuation metrics of similar companies.Big Pharma is currently under evaluation in net income category among its peers.
Big Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Big Pharma from analyzing Big Pharma's financial statements. These drivers represent accounts that assess Big Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Big Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 18.9M | 22.0M | 17.4M | 14.9M | 13.4M | 13.7M | |
| Enterprise Value | 32.3M | 31.0M | 27.5M | 25.5M | 29.3M | 30.7M |
Big Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.031 | ||||
| Operating Margin | 1.41 % | ||||
| Current Valuation | (9.41 M) | ||||
| Shares Outstanding | 1.22 M | ||||
| Number Of Shares Shorted | 3.23 K | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 4.27 X | ||||
| Revenue | 1.85 M | ||||
| Gross Profit | (664.73 K) | ||||
| EBITDA | 21.36 K | ||||
| Net Income | (538.62 K) | ||||
| Total Debt | 11.57 M | ||||
| Book Value Per Share | 10.81 X | ||||
| Cash Flow From Operations | (1.3 M) | ||||
| Short Ratio | 3.56 X | ||||
| Earnings Per Share | (1.95) X | ||||
| Target Price | 2.0 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 17.91 M | ||||
| Total Asset | 26.3 M | ||||
| Annual Yield | 0.11 % | ||||
| Net Asset | 26.3 M | ||||
| Last Dividend Paid | 1.24 |
About Big Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Big Pharma Split's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Big Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Big Pharma Split based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.